We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.
- Authors
Huang, Zhengnan; Yan, Yilin; Wang, Tengjiao; Wang, Zeyi; Cai, Jinming; Cao, Xiangqian; Yang, Chenkai; Zhang, Fang; Wu, Gang; Shen, Bing
- Abstract
<bold>Background: </bold>Enolase is an essential enzyme in the process of glycolysis and has been implicated in cancer progression. Though dysregulation of ENOs has been reported in multiple cancers, their prognostic value and specific role in bladder cancer (BLCA) remain unclear.<bold>Methods: </bold>Multiple databases were employed to examine the expression of ENOs in BLCA. The expression of ENO1 was also validated in BLCA cell lines and tissue samples by western blotting and immunohistochemistry. Kaplan-Meier analysis, ROC curve, univariate and multivariate Cox regression were performed to evaluate the predictive capability of the ENO1. Gene ontology (GO) and Gene Set Enrichment Analyses (GSEA) analysis were employed to perform the biological processes enrichment. Function experiments were performed to explore the biological role of ENO1 in BLCA. The correlation of ENO1 with immune cell infiltration was explored by CIBERSORT.<bold>Results: </bold>By analyzing three ENO isoforms in multiple databases, we identified that ENO1 was the only significantly upregulated gene in BLCA. High expression level of ENO1 was further confirmed in BLCA tissue samples. Aberrant ENO1 overexpression was associated with clinicopathological characteristics and unfavorable prognosis. Functional studies demonstrated that ENO1 depletion inhibited cancer cell aggressiveness. Furthermore, the expression level of ENO1 was correlated with the infiltration levels of immune cells and immune-related functions.<bold>Conclusions: </bold>Taken together, our results indicated that ENO1 might serve as a promising prognostic biomarker for prognosticating prognosis associated with the tumor immune microenvironment, suggesting that ENO1 could be a potential immune-related target against BLCA.
- Subjects
DRUG target; BLADDER cancer; BIOMARKERS; PROGNOSIS; RECEIVER operating characteristic curves; TARGETED drug delivery
- Publication
Journal of Translational Medicine, 2022, Vol 20, Issue 1, p1
- ISSN
1479-5876
- Publication type
journal article
- DOI
10.1186/s12967-022-03509-1